TY - CONF
T1 - Association of the clinical presentation and disease activity index in Sjogren's syndrome
AU - Petrakovs, Maksims
AU - Mihailova, Anna
PY - 2021/3/24
Y1 - 2021/3/24
N2 - Investigate the impact of different clinical presentation on disease activity in patients with primary Sjogren’s syndrome. The retrospective study including data about 40 outpatients who visited a rheumatologist in SIA “ORTO klīnika” from 2014 to 2020 with diagnosis defined as M35.0 by the ICD-10. Disease activity measured by EULAR Sjogren’s syndrome activity index (ESSDAI). 40 patients – 36 women and 4 men with mean age 55.5 years (±2.14; SD=13.55). Average disease manifestation age – 48.4 years (±1.93; SD=12.23), average disease activity index – 12.6 points (±1.28; SD=8.1). Complains about dry mouth had 32 patients, dry eyes – 26, parotid gland enlargement or ultrasonographic inflammation – 23, articular involvement – 26, renal – 20, skin – 9, lungs – 9, neural – 7. Changes in complete blood count tests were common finding: lymphopenia was observed in 15 patients, anaemia -12, leukopenia or neutropenia -10, thrombocytopenia -3. Immunological changes were found in majority of patients: ANA had 39 patients, ENA -38, SS-A/Ro -36, SS-B/La -19, rheumatoid factor -29, polyclonal hypergammaglobulinemia -27, hypocomplementemia -12 (only 25 from 40 checked).
Higher disease activity index was in association with lymphopenia (16.6 vs 10.2 points; p=0.014), anaemia (18.1 vs 10.77 points; p=0.011), renal (14.85 vs 10.35 points; p=0.017) and lung (18.89 vs 10.77 points; p=0.006) involvement, lower disease activity – in association with articular involvement (10.54 vs 16.43 points; p=0.026).
Lymphocyte count (k=-0.48; p=0.02) and ANA (k=0.51; p=0.002) moderately correlates with disease activity index, rheumatoid factor level – have only weak correlation (k=0.334; p=0.04). Anaemia, lymphopenia, renal and lung involvement associated with more severe disease course, but articular involvement – with less severe. High antinuclear antibody and rheumatoid factor level are characteristic for Sjogren’s syndrome and important in the diagnosis, but are not strong markers of the disease activity.
AB - Investigate the impact of different clinical presentation on disease activity in patients with primary Sjogren’s syndrome. The retrospective study including data about 40 outpatients who visited a rheumatologist in SIA “ORTO klīnika” from 2014 to 2020 with diagnosis defined as M35.0 by the ICD-10. Disease activity measured by EULAR Sjogren’s syndrome activity index (ESSDAI). 40 patients – 36 women and 4 men with mean age 55.5 years (±2.14; SD=13.55). Average disease manifestation age – 48.4 years (±1.93; SD=12.23), average disease activity index – 12.6 points (±1.28; SD=8.1). Complains about dry mouth had 32 patients, dry eyes – 26, parotid gland enlargement or ultrasonographic inflammation – 23, articular involvement – 26, renal – 20, skin – 9, lungs – 9, neural – 7. Changes in complete blood count tests were common finding: lymphopenia was observed in 15 patients, anaemia -12, leukopenia or neutropenia -10, thrombocytopenia -3. Immunological changes were found in majority of patients: ANA had 39 patients, ENA -38, SS-A/Ro -36, SS-B/La -19, rheumatoid factor -29, polyclonal hypergammaglobulinemia -27, hypocomplementemia -12 (only 25 from 40 checked).
Higher disease activity index was in association with lymphopenia (16.6 vs 10.2 points; p=0.014), anaemia (18.1 vs 10.77 points; p=0.011), renal (14.85 vs 10.35 points; p=0.017) and lung (18.89 vs 10.77 points; p=0.006) involvement, lower disease activity – in association with articular involvement (10.54 vs 16.43 points; p=0.026).
Lymphocyte count (k=-0.48; p=0.02) and ANA (k=0.51; p=0.002) moderately correlates with disease activity index, rheumatoid factor level – have only weak correlation (k=0.334; p=0.04). Anaemia, lymphopenia, renal and lung involvement associated with more severe disease course, but articular involvement – with less severe. High antinuclear antibody and rheumatoid factor level are characteristic for Sjogren’s syndrome and important in the diagnosis, but are not strong markers of the disease activity.
M3 - Abstract
SP - 484
T2 - RSU Research week 2021: Knowledge for Use in Practice
Y2 - 24 March 2021 through 26 March 2021
ER -